Literature DB >> 3109736

Augmentation of the generation of cell-mediated cytotoxicity in culture by mitomycin C.

T Akiyoshi, S Arinaga, H Tsuji.   

Abstract

The effects of mitomycin C (MMC) on the generation of cell-mediated cytotoxicity in primary stimulation culture of human peripheral blood mononuclear cells (PBM) with the B lymphoblastoid Raji cell line were assessed. The cell-mediated cytotoxicity induced in culture was significantly augmented when MMC was added to cultures on day -1 to day 3 for 24 h at concentrations of 2.5 X 10(-2) micrograms/ml and 2.5 X 10(-3) micrograms/ml. To identify the cell populations affected by MMC, PBM were separated by adherence to plastic after treatment with MMC for 24 h (day -1). The two populations were recombined with untreated separated cells and stimulated with antigen. The ability to develop an augmented cell-mediated cytotoxicity was associated with the adherent cell fraction of MMC-treated PBM. Therefore, the ability of MMC-treated adherent cells to produce interleukin 1 (IL 1) was examined. Significantly higher levels of IL 1 were produced by treated cells as compared to untreated adherent cells. The results appear to indicate that the selective effects of MMC on the adherent cell fraction, especially the modification of IL 1 production, may be involved in the mechanisms of MMC-induced augmented cell-mediated cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3109736     DOI: 10.1007/bf00205640

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  11 in total

1.  Augmentation of the cell-mediated cytotoxic response induced in mixed cell culture by adriamycin.

Authors:  S Arinaga; T Akiyoshi; H Tsuji
Journal:  Jpn J Cancer Res       Date:  1985-05

2.  In vitro tumor cell killing by peritoneal macrophages from mitomycin C-treated rats.

Authors:  T Ogura; H Shindo; O Shinzato; M Namba; T Masuno; T Inoue; S Kishimoto; Y Yamamura
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

3.  Modulation of the cytotoxic response against allogeneic tumor cells in culture by adriamycin.

Authors:  V Tomazic; M J Ehrke; E Mihich
Journal:  Cancer Res       Date:  1980-08       Impact factor: 12.701

4.  In vitro augmentation of human natural cytotoxic activity.

Authors:  M R Potter; M Moore
Journal:  Clin Exp Immunol       Date:  1981-05       Impact factor: 4.330

5.  Augmentation of the development of immune responses of mice against allogeneic tumor cells after adriamycin treatment.

Authors:  V Tomazic; M J Ehrke; E Mihich
Journal:  Cancer Res       Date:  1981-09       Impact factor: 12.701

6.  Adriamycin-induced activation of NK activity may initially involve LAF production.

Authors:  S A Cohen; D Salazar; J Wicher
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

7.  Correlation between adriamycin-induced augmentation of interleukin 2 production and of cell-mediated cytotoxicity in mice.

Authors:  M J Ehrke; D Maccubbin; K Ryoyama; S A Cohen; E Mihich
Journal:  Cancer Res       Date:  1986-01       Impact factor: 12.701

8.  Augmentation of the generation of cell-mediated cytotoxicity after a single dose of adriamycin in cancer patients.

Authors:  S Arinaga; T Akiyoshi; H Tsuji
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

9.  Increased primary cell-mediated immunity in culture subsequent to adriamycin or daunorubicin treatment of spleen donor mice.

Authors:  F Orsini; Z Pavelic; E Mihich
Journal:  Cancer Res       Date:  1977-06       Impact factor: 12.701

10.  Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice.

Authors:  H Shindo; T Ogura; T Masuno; S Hayashi; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

View more
  4 in total

1.  The effect of recombinant interleukin 2 in combination with mitomycin C on advanced cancer.

Authors:  T Akiyoshi; S Arinaga; S Nanbara; N Karimine; H Inoue; K Takamuku; R Abe; D Watanabe; M Nagamatsu; H Matsuoka
Journal:  Jpn J Surg       Date:  1990-05

2.  Augmentation of the generation of lymphokine-activated killer cells after a single dose of mitomycin C in cancer patients.

Authors:  S Nanbara; S Arinaga; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Immunohistochemical analysis of lymphocyte subsets infiltrating gastric carcinoma after mitomycin C administration.

Authors:  H Inoue; M Adachi; N Karimine; S Arinaga; H Ueo; D Korenaga; T Akiyoshi
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

4.  A murine plasmacytoma MOPC 104E resistant to cyclophosphamide is resistant to immunotherapy.

Authors:  K Satoh; N Kan; T Okino; M Nakanishi; K Mise; Y Teramura; S Yamasaki; K Ohgaki; T Tobe
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.